Search for: "Doe Pharmaceutical"
Results 1 - 20
of 7,509
Sort by Relevance
|
Sort by Date
4 Jun 2024, 3:00 am
This suit does not seek to regulate emissions and does not seek damages for interstate emissions,” the state court said in a unanimous opinion. [read post]
2 Jun 2024, 5:08 am
Background In 2012, Insys Therapeutics, a pharmaceutical company, was sued in a qui tam action under the False Claims Act. [read post]
2 Jun 2024, 4:47 am
Particularly, according to the Board: "while the basis for proceeding with the pharmaceutical development of a compound is favourable preclinical data, this does not necessarily give rise to a well-founded expectation of success, even less in the case of a combination product when neither combination partner has, as yet, progressed to the clinical stage of development". [read post]
31 May 2024, 10:44 am
§ 253 and concluded that “the invalidity of … claim 1 because of double patenting, even if true, does not necessarily require the invalidation of claims 5, 19, 40, and 43. [read post]
31 May 2024, 6:04 am
Eli Lilly is the only authorized supplier of FDA-approved tirzepatide medicines in the U.S. and does not provide tirzepatide’s active pharmaceutical ingredient (API) to any compounding pharmacies. [read post]
30 May 2024, 10:00 pm
In what is being touted as a significant win for pharmaceutical drug manufacturers, the DC Circuit affirmed on May 21, 2024 that Section 340B of the Public Health Service Act does not categorically prohibit manufacturers from imposing distribution restrictions on covered drugs to covered entities. [read post]
30 May 2024, 10:00 pm
In what is being touted as a significant win for pharmaceutical drug manufacturers, the DC Circuit affirmed on May 21, 2024 that Section 340B of the Public Health Service Act does not categorically prohibit manufacturers from imposing distribution restrictions on covered drugs to covered entities. [read post]
30 May 2024, 10:00 pm
In what is being touted as a significant win for pharmaceutical drug manufacturers, the DC Circuit affirmed on May 21, 2024 that Section 340B of the Public Health Service Act does not categorically prohibit manufacturers from imposing distribution restrictions on covered drugs to covered entities. [read post]
30 May 2024, 10:00 pm
In what is being touted as a significant win for pharmaceutical drug manufacturers, the DC Circuit affirmed on May 21, 2024 that Section 340B of the Public Health Service Act does not categorically prohibit manufacturers from imposing distribution restrictions on covered drugs to covered entities. [read post]
30 May 2024, 10:00 pm
In what is being touted as a significant win for pharmaceutical drug manufacturers, the DC Circuit affirmed on May 21, 2024 that Section 340B of the Public Health Service Act does not categorically prohibit manufacturers from imposing distribution restrictions on covered drugs to covered entities. [read post]
30 May 2024, 10:00 pm
In what is being touted as a significant win for pharmaceutical drug manufacturers, the DC Circuit affirmed on May 21, 2024 that Section 340B of the Public Health Service Act does not categorically prohibit manufacturers from imposing distribution restrictions on covered drugs to covered entities. [read post]
30 May 2024, 7:34 pm
/Novartis Pharmaceuticals v. [read post]
24 May 2024, 12:47 pm
(Queries an observer: if the dog alerts to both things that are illegal, like drugs, and things that might be legal, like people, how does that make the search more justified?) [read post]
24 May 2024, 4:35 am
Specifically, the court found that the 340B statute does not forbid manufacturers from limiting the distribution of discounted drugs by contract. [read post]
19 May 2024, 9:05 pm
Nov 21, 2023 | Does Industry Self-Regulation of Mental Health Apps Protect Consumers? [read post]
19 May 2024, 2:55 am
In the pharmaceutical field, for example, the prior disclosure of a specific chemical structure of a drug destroys the novelty of a claim for that drug per se. [read post]
17 May 2024, 1:07 pm
On the other, it encourages generic pharmaceutical manufacturers to challenge name-brand patents while antitrust law prohibits anticompetitive deals. [read post]
15 May 2024, 1:56 pm
Food and Drug Administration’s regulations and guidance documents for pharmaceutical companies are unclear and continue to emphasize the use of animals for drug testing. [read post]
15 May 2024, 2:33 am
The petition submitted outlines specific actions that the FDA should take to rectify this situation: Amend its regulations to make it clear that the FDA does not require animal testing for drugs. [read post]
13 May 2024, 5:58 pm
Does Carol know this? [read post]
